Remdesivir has received emergency use authorization (EUA) from the U.S. Food and Drug Administration after a major study showed that it can reduce recovery time for hospitalized COVID-19 patients.

In a news release on Friday, the FDA said it has issued the EUA for “treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.”

Gilead’s investigational antiviral for the treatment of COVID-19 receives @US_FDA Emergency Use Authorization. This more readily enables treatment of hospitalized patients with severe COVID-19 disease in the United States. Read more: https://t.co/p4LR0RM7sI. pic.twitter.com/4kg9oDQPRq

— Gilead Sciences (@GileadSciences) May 1, 2020

Story continues below advertisement

The FDA acknowledged there is “limited information” so far about how effective or safe the drug is.

Preliminary results from a 1,063-patient clinical trial by the U.S. National Institutes of Health showed that patients given remdesivir recovered in a shorter than those given a placebo.

1:39Remdesivir: Drug shows promise as COVID-19 treatment

Remdesivir: Drug shows promise as COVID-19 treatment

U.S.

 » READ MORE FROM GLOBAL NEWS